Methods: We performed a systematic review and meta‐analysis of randomized clinical trials (RCTs) comparing GLP‐1R agonists to placebo or best medical therapy (BMT) in patients with mild to moderate PD. This evidence concerns the gene GLP1R and Parkinson disease.